collabor
research
project
chemist
biologist
medic
scientist
inevit
produc
mani
use
drug
biosensor
medic
instrument
organ
chemistri
lie
heart
drug
discoveri
develop
current
rang
organ
synthet
methodolog
allow
construct
unlimit
librari
small
organ
molecul
drug
screen
translat
research
project
focus
discoveri
lead
compound
three
major
diseas
alzheim
diseas
ad
breast
cancer
viral
infect
ad
project
taken
rationaldesign
approach
synthes
new
class
tricycl
pyron
tp
compound
preserv
memori
motor
function
amyloid
precursor
protein
app
mice
tp
could
protect
neuron
death
sever
possibl
mechan
includ
abil
inhibit
format
intraneuron
extracellular
amyloid
b
ab
aggreg
increas
cholesterol
efflux
restor
axon
traffick
enhanc
longterm
potenti
ltp
restor
ltp
follow
treatment
ab
oligom
also
synthes
new
class
gapjunct
enhanc
base
substitut
quinolin
possess
potent
inhibitori
activ
breastcanc
cell
vitro
vivo
although
variou
antivir
drug
avail
emerg
viral
resist
exist
antivir
drug
variou
understudi
viral
infect
noroviru
rotaviru
emphas
demand
develop
new
antivir
agent
infect
other
laboratori
undertaken
project
discoveri
new
antivir
inhibitor
discuss
aforement
project
may
shed
light
futur
develop
drug
candid
field
ad
cancer
viral
infect
asymmetr
induct
reaction
use
chiral
allyl
sulfoxid
phosphonamid
chiral
sulfinyl
ketimin
chiral
sulfinylimin
well
util
reaction
synthesi
natur
product
last
twenti
year
group
investig
design
synthesi
evalu
bioactiv
small
molecul
new
compound
base
naturalproduct
scaffold
along
synthesi
challeng
molecul
bioactiv
compound
rang
anticanc
molecul
contain
anthracenedion
triptycen
bisquinon
substitutedquinolin
moieti
tricycl
pyron
molecul
amelior
ad
antimalari
agent
antivir
agent
person
account
describ
three
translat
research
project
carri
laboratori
involv
discoveri
bioactiv
compound
lead
compound
treatment
ad
breast
cancer
viral
infect
million
peopl
worldwid
suffer
ad
current
avail
treatment
ad
donepezil
rivastigmin
galantamin
memantin
temporarili
amelior
symptom
modifi
underli
diseas
urgent
need
challeng
discoveri
new
drug
treat
diseas
discov
new
class
tricycl
pyron
possess
high
oral
bioavail
excel
permeabl
bloodbrain
barrier
low
toxic
pyron
substanti
decreas
number
solubl
insolubl
ab
speci
brain
preserv
memori
motor
function
ad
transgen
mice
tumor
cell
imped
alter
celltocel
commun
one
type
cellcel
commun
gap
junction
synthes
librari
substitut
quinolin
found
sever
compound
possess
potent
inhibitori
activ
breastcanc
cell
enhanc
gapjunct
intercellular
commun
gjic
compound
reduc
xenograft
breast
tumor
mice
complet
erad
tumor
format
spontan
transgen
mammari
mice
viral
infect
includ
influenza
respons
million
case
ill
half
million
death
per
year
although
antivir
drug
certain
viral
infect
avail
emerg
viral
resist
exist
antivir
drug
emphas
demand
develop
new
antivir
drug
synthes
bioevalu
sever
class
antivir
compound
includ
triacsin
c
analogu
acat
inhibitor
antioxid
quercetin
analogu
ad
progress
neurodegen
disord
common
form
dementia
elderli
million
american
million
peopl
worldwid
suffer
ad
present
avail
treatment
ad
temporarili
allevi
symptom
treat
cure
underli
diseas
caus
ad
remain
elus
initi
cholinerg
hypothesi
decreas
synthesi
neurotransmitt
acetylcholin
complet
explain
pathogenesi
amyloid
tau
hypothes
receiv
attent
brain
patient
ad
present
two
classic
lesion
extracellular
amyloid
plaqu
intracellular
neurofibrillari
tangl
aggreg
amyloidb
ab
peptid
residu
protein
wide
consid
initi
cascad
molecular
chang
lead
ad
product
ab
result
sequenti
proteolyt
process
amyloid
precursor
protein
app
band
gsecretas
presenilin
major
compon
gsecretas
compris
two
isoform
presenilin
ps
autosomaldomin
famili
form
ad
attribut
mutat
app
emerg
evid
support
conclus
solubl
oligom
abbut
monom
insolubl
amyloid
fibrilsmay
primari
toxic
amyloid
caus
synapt
dysfunct
brain
anim
model
ad
lownoligom
ab
dimer
highnoligom
mer
ab
implic
directli
caus
impair
synapt
plastic
memori
case
ad
howev
sporad
late
onset
major
genet
risk
factor
includ
inherit
allel
apolipoprotein
e
apo
geneencod
apo
increas
risk
ad
heterozygot
homozygot
thu
suggest
import
role
cholesterol
homeostasi
ad
major
strategi
experiment
diseasemodifi
therapi
includ
target
multipl
site
metabol
ab
synthesi
aggreg
deposit
clearanc
target
tau
inhibit
tau
phosphoryl
prevent
tau
aggreg
andor
disaggreg
tau
aggreg
regul
cholesterol
level
antiexcitotox
antiinflamm
modul
calcium
homeostasi
among
other
fdaapprov
drug
delay
halt
progress
diseas
major
focu
ad
research
develop
drugtarget
amyloid
tau
research
goal
therefor
discoveri
develop
new
molecul
slow
revers
ad
progress
reduc
amyloid
patholog
maintain
cholesterol
homeostasi
brain
studi
synthesi
new
acylcoa
cholesterol
acyltransferas
acat
inhibitor
base
natur
product
pyripyropen
synthes
new
class
tricycl
pyron
molecul
contain
three
four
ring
pyripyropen
nucleu
base
initi
screen
result
variou
tricycl
pyron
molecul
use
cell
comput
dock
experi
ab
fibril
code
name
analogu
design
acat
convert
membran
cholesterol
cytoplasm
cholesterylest
droplet
storag
acat
inhibitor
implic
antiatherosclerosi
reduct
amyloid
patholog
regul
cholesterol
homeostasi
tricycl
pyron
molecul
synthes
four
step
condens
commerci
avail
perillaldehyd
select
hydrobor
result
tricycl
pyron
boran
follow
treatment
hydrogen
peroxid
mesyl
methanesulfonyl
chlorid
displac
reaction
adenin
figur
singl
enantiom
compound
form
condens
reaction
howev
mixtur
two
diastereom
possess
r
configur
posit
produc
hydrobor
process
synthesi
synthes
librari
tricycl
pyron
tp
molecul
screen
neuronalprotect
activ
use
cell
induc
ab
oligom
identifi
seven
mostact
compound
includ
minimum
effect
dosag
cell
surviv
valu
rang
nm
toxic
effect
cell
death
presenc
tetracyclin
valu
rang
mm
therapeut
index
ti
therapeut
ratio
valu
respect
line
human
neuroblastoma
condit
express
carboxyl
termin
fragment
deriv
bsecretas
cleavag
app
subsequ
cleav
gsecretas
gener
ab
signific
loss
cell
viabil
occur
h
follow
transgen
induct
absenc
tetracyclin
cell
death
caus
factor
media
includ
secret
ab
demonstr
cell
death
depend
cellular
product
accumul
ab
possibl
aggreg
form
present
sdsstabl
ab
oligomer
complex
cell
easili
propag
cell
toxic
measur
quantit
simpl
bromid
mtt
assay
understand
mechan
action
class
compound
use
surfac
plasmon
reson
spectroscopi
show
tp
compound
bind
oligom
atom
forc
microscopi
reveal
tp
compound
inhibit
aggreg
peptid
disaggreg
oligom
protofibril
real
time
circular
dichroism
monitor
protein
conform
presenc
tp
peptid
remain
random
coil
structur
protein
quantif
verifi
tp
compound
inhibit
format
fibril
moreov
cell
studi
found
tp
reduc
accumul
ab
peptid
ab
oligom
normal
cholesterol
level
cell
inhibit
acat
activ
increas
cholesteroltransport
gene
therebi
result
modul
cholesterol
efflux
neuron
insolut
cellbas
studi
suggest
tp
compound
possess
antiamyloid
properti
modul
cholesterol
homeostasi
neuron
instanc
found
inhibit
acat
valu
mm
increas
cholesteroltransport
gene
valu
mm
activ
tp
compound
similar
greater
valu
acat
inhibit
valu
enhanc
gene
also
investig
effect
tp
compound
basal
neurotransmiss
synapt
plastic
rathippocamp
slice
measur
ltp
found
addit
amyloid
b
oligom
abo
block
ltp
induct
nanomolar
rang
perfus
tp
compound
mm
prior
coapplic
abo
restor
ltp
nonabotr
level
moreov
tp
alon
also
significantli
enhanc
magnitud
ltp
without
affect
basal
synapt
activ
thu
impli
tp
block
aboinduc
toxic
preserv
hippocamp
synapt
plastic
tp
compound
appear
possess
multipl
benefici
effect
evalu
bioavail
tp
compound
employ
number
techniqu
octanolwat
partit
experi
log
p
valu
obtain
respect
suggest
readili
enter
brain
furthermor
perform
liquid
scintil
analysi
radioact
brain
ip
inject
clabel
mice
found
readili
enter
brain
short
amount
time
min
also
use
alogp
program
calcul
log
p
valu
well
tp
compound
averag
log
p
valu
rang
calcul
log
p
valu
indic
tp
compound
similar
braincapillari
permeabl
therefor
also
readili
penetr
bloodbrain
barrier
bbb
oral
administr
would
ideal
futur
therapeut
applic
determin
amount
along
sever
activ
tp
compound
plasma
brain
oral
gavag
administr
mice
known
amount
acid
bta
intern
standard
ad
plasma
tissu
tp
bta
extract
plasma
brain
tissu
mice
extract
contain
bta
tp
subject
hplc
analysi
amount
tp
deduc
ratio
integr
peak
bta
tp
hplc
trace
result
show
concentr
reach
mm
brain
h
respect
follow
administr
mg
kg
thu
indic
good
bbb
penetr
tp
compound
similar
concentr
brain
vivo
efficaci
evalu
use
ad
transgen
mice
collabor
leeway
jin
previous
twoweek
intraventricular
infus
mm
ngday
brain
mice
substanti
decreas
level
solubl
insolubl
ab
respect
tp
compound
could
reach
brain
concentr
mm
follow
oral
administr
mg
kg
effect
week
twicedaili
oral
treatment
cerebr
ab
deposit
studi
treatment
elimin
amyloid
load
figur
ab
dimer
shown
caus
memori
deficit
rodent
main
speci
solubl
ab
oligom
mice
evalu
level
ab
dimer
tbssolubl
brain
extract
western
blot
found
mice
show
substanti
lower
level
solubl
ab
dimer
figur
evalu
improv
memori
motor
function
transgen
mice
treatment
collabor
eugenia
trishina
mice
character
amyloid
deposit
adlik
behavior
memori
deficit
earli
week
administ
drink
water
mg
kg
daili
nontransgen
ntg
litterm
n
per
group
mice
month
new
objectrecognit
test
month
motorabnorm
studi
use
hang
bar
rotarod
test
acid
salt
use
vivo
studi
complet
water
solubl
tasteless
interfer
anim
normal
water
consumpt
treatment
enhanc
memori
perform
mice
level
differ
ntg
control
mice
treatment
improv
motor
abnorm
mice
well
mice
treat
show
improv
perform
differ
ntg
mice
rotarod
test
app
mice
outperform
vehicletr
app
mice
mice
perform
better
agematch
ntg
mice
notabl
appar
drug
toxic
observ
cours
treatment
tp
abnorm
histopatholog
hematolog
count
blood
chemistri
found
necropsi
mice
summari
encourag
patholog
behavior
data
provid
strong
rational
futur
therapeut
studi
commun
cell
mediat
gap
junction
gj
regul
cell
prolifer
apoptosi
differenti
gj
intercellular
membran
channel
gj
channel
contain
one
differ
connexin
cx
protein
form
gapjunct
plaqu
larg
cluster
gap
junction
channel
figur
show
topolog
cx
along
gj
channel
six
cx
aggreg
form
hemichannel
connexon
hemichannel
dock
anoth
adjac
cell
form
dodecamer
gj
channel
channel
activ
measur
passag
small
dye
molecul
molecular
weight
da
one
cell
anoth
shown
defect
gjic
may
involv
carcinogenesi
process
gj
frequent
decreas
absent
cancer
cell
loss
gjic
carcinogenesi
may
result
direct
disrupt
specif
connexin
gene
mrna
level
cx
synthes
endoplasm
reticulum
transport
golgi
apparatu
transgolgi
network
plasma
membran
cx
reach
plasma
membran
oligomer
connexon
newli
synthes
connexon
ad
onto
peripheri
exist
gap
junction
dock
connexon
adjac
cell
connexon
degrad
phosphoryl
protein
kinas
c
pkc
mitogenactiv
protein
kinas
mapk
serin
residu
molecular
weight
kda
follow
ubiquitin
phosphoryl
step
result
alter
conform
bind
alter
connexin
fig
twomonthold
mice
treat
vehicl
mock
week
describ
cortic
section
immunostain
ab
use
monoclon
antibodi
numer
amyloid
plaqu
indic
red
arrow
seen
vehicletr
mice
scarc
amount
small
plaqu
seen
mice
b
c
quantif
abimmunoreact
area
show
signific
differ
two
sampl
n
p
solubl
fraction
brain
analyz
ab
dimer
western
blot
recruit
ubiquitin
therebi
lead
ubiquitin
disassembl
connexon
furthermor
pkca
overexpress
shown
caus
tumor
growth
tumor
resist
cytotox
chemotherapi
multipl
vitro
studi
confirm
loss
connexin
andor
gjic
breastcanc
cell
significantli
increas
cellcel
commun
tumor
cell
enhanc
drug
sensit
search
gjic
enhanc
carri
comput
dock
studi
connexon
pkca
variou
small
molecul
discov
class
substitut
quinolin
bind
connexon
pkca
librari
substitutedquinolin
compound
term
pq
synthes
evalu
anticanc
activ
vitro
use
breastcanc
cell
found
sever
pq
compound
possess
anticanc
activ
nanomolar
rang
synthesi
structur
pq
compound
illustr
figur
vivo
anticanc
efficaci
pq
compound
evalu
use
nude
mice
nunu
mice
treat
show
signific
reduct
xenograft
tumor
growth
cell
compar
control
tamoxifentr
mice
moreov
nunu
mice
show
regress
xenograft
tumor
growth
combin
treatment
tamoxifen
enhanc
anticanc
effect
tamoxifen
thu
impli
deeper
penetr
anticanc
drug
cancer
mass
pqenhanc
gjic
synergist
anticanc
activ
collabor
thu
nguyen
recent
develop
transgen
mous
model
mammari
tumor
lower
level
connexin
express
compar
control
nontransgen
mice
preliminari
result
show
treatment
two
week
could
complet
prevent
tumor
format
mice
compar
control
pursuit
mechan
action
pq
use
dye
lucif
yellow
experi
demonstr
enhanc
gjic
pqtreat
cell
found
increas
express
spontan
mammari
tumor
upon
treatment
decreas
phosphoryla
tion
serin
residu
cell
consequ
studi
inhibit
phosphoryl
pkc
enzym
assay
conduct
commerci
avail
peptag
nonradioact
pkc
assay
kit
promega
use
studi
inhibit
pkc
pq
compound
valu
staurosporin
known
pkc
inhibitor
found
nanomolar
rang
inact
pq
use
neg
control
inhibit
phosphoryl
found
mm
henc
pkcinhibitori
activ
pq
appear
correl
overal
xenograft
spontan
tumor
studi
show
excit
result
demonstr
pq
compound
attenu
tumor
growth
outcom
find
provid
new
class
anticanc
molecul
well
tool
regul
gjic
viral
infect
caus
virus
multipli
host
cell
virus
made
genet
dna
rna
materi
protect
protein
outer
envelop
lipid
henc
three
compon
main
target
antivir
agent
herein
summar
studi
inhibitor
longchain
fattyacid
acylcoa
synthetas
acsl
acat
well
analogu
antioxid
quercetin
figur
number
year
laboratori
interest
lipogenesi
eg
see
section
involv
synthesi
fatti
acid
acetylcoa
subsequ
esterif
glycerol
form
triglycerid
lipogenet
enzym
includ
fattyacid
synthas
fasn
acsl
diacylglycerol
acyltransferas
dgat
acylcoa
cholesterol
commerci
avail
inhibitor
fasn
acsl
dgat
acat
found
significantli
reduc
replic
rotavirus
vitro
collabor
kyeongok
chang
investig
analogu
triacsin
c
tc
fungal
metabolit
streptomyc
aureofacien
show
mostpot
inhibit
rotaviru
replic
overexpress
andor
activ
lipogen
enzym
found
cancer
henc
acsl
inhibitor
may
use
reduct
cancer
growth
synthet
sequenc
tc
compound
straightforward
effici
figur
provid
flexibl
optim
start
known
aldehyd
synthes
evalu
along
analogu
notabl
triacsin
c
difficult
compound
prepar
suffici
amount
avail
vivo
studi
among
triacsin
c
analogu
potent
rotaviru
replic
valu
effect
dose
reduc
viru
replic
mm
therefor
tc
analogu
may
use
lead
compound
rotaviru
infect
possibl
cancer
therapi
lipogen
enzym
acsl
may
repres
potenti
therapeut
target
noroviru
belong
calicivirida
famili
small
nonenvelop
rna
virus
nm
diamet
present
specif
drug
treatment
noroviru
infect
norovirus
grow
cell
cultur
show
high
divers
demonstr
immun
heterolog
strain
develop
vaccin
face
stiff
challeng
current
unavail
perform
dna
microarray
analysi
noroviru
repliconharbor
cell
affymetrix
gene
chip
collabor
kyeongok
chang
increas
cholesterol
modul
gene
fold
found
henc
librari
acat
inhibitor
pyranobenzopyron
compound
pb
synthes
evalu
inhibitori
activ
cell
compound
possess
strongest
activ
among
test
librari
compound
ti
valu
list
figur
valu
low
micromolar
rang
investig
class
compound
need
improv
potenc
virus
live
insid
host
cell
target
lipogenet
enzym
inevit
show
toxic
side
effect
antioxid
polyphenol
quercetin
deriv
quercetin
quercetin
found
effect
influenza
infect
effect
treatment
inflammatori
bowel
diseas
inhibit
na
k
atpas
andor
na
h
exchang
activ
base
result
studi
hybrid
quercetin
gallat
substitu
activ
figur
small
librari
deriv
gallat
moieti
quercetin
show
compar
antivir
activ
influenza
viru
porcin
egcg
improv
vitro
therapeut
index
deriv
possess
variou
polyhydroxylbenzo
aminohydroxybenzo
function
posit
less
effect
compound
contain
aminoalkoxi
alkoxi
substitu
posit
lower
antivir
activ
qc
compound
readili
synthes
modif
posit
may
improv
efficaci
combin
treatment
inhibitor
lipogenesi
antioxid
may
produc
synergist
result
synthet
organ
chemistri
provid
abund
methodolog
construct
bioactiv
compound
protein
crystallographi
comput
dock
softwar
use
infus
predict
factor
design
util
tool
variou
bioactiv
compound
includ
antiad
antibreastcanc
antivir
agent
produc
antiad
compound
good
bioavail
shown
efficaci
ad
transgen
mous
model
reduc
amyloid
plaqu
improv
cognit
motor
function
gjic
enhanc
kill
breastcanc
cell
vitro
vivo
investig
two
class
compound
largerscal
pharmacokineticpharmacodynam
toxic
studi
warrant
continu
search
antivir
agent
viral
proteas
inhibitor
pursu
despit
tremend
endeavor
made
chymotrypsinlik
serin
proteas
hepat
c
viru
pepsinlik
aspart
proteas
human
immunodefici
viru
hiv
chymotrypsinlik
papainlik
cystein
proteas
picornaviru
caliciviru
coronaviru
hepat
viru
well
coxsackieviru
enteroviru
proteas
hand
foot
mouth
diseas
asept
mening
name
less
studi
